U-shaped Relationship of Blood Pressure to CVD Risk and Relevance to Treatment Goals in Diabetes

Diabetes and Insulin Resistance (M Rutter, Section Editor)
  • 85 Downloads
Part of the following topical collections:
  1. Topical Collection on Diabetes and Insulin Resistance

Abstract

A heated debate has developed on the blood pressure goal for treatment of hypertension in patients with type 2 diabetes. The evidence for going below 130 mmHg systolic blood pressure has been found to be weak and that is why new guidelines have advocated a somewhat more conservative view, aiming for a blood pressure goal <140/85 mmHg in European guidelines and <140/80 mmHg in American guidelines from 2013. One important argument has been the description of a J-shaped curve for associations between achieved blood pressure levels in the trials and risk of cardiovascular events. These observational data have contributed to the change in attitudes for defining blood pressure goals in patients with type 2 diabetes, and will be briefly summarised here. Not only post hoc observational data from clinical trials will be discussed but also observational data from a National Diabetes Register, covering 2/3 of all diabetes patients in Sweden.

Keywords

Cardiovascular Diabetes Drugs Epidemiology Hypertension Risk Treatment 

References

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. 1.
    Adler AI, Stratton IM, Neil HA, et al. Association of systolic blood pressure with macrovascular and microvascular complications of type 2 diabetes (UKPDS 36): prospective observational study. BMJ. 2000;321:412–9.PubMedCrossRefGoogle Scholar
  2. 2.
    Bonora E, Capaldo B, Perin PC, Group of Italian Scientists of Insulin Resistance (GISIR), et al. Hyperinsulinemia and insulin resistance are independently associated with plasma lipids, uric acid and blood pressure in non-diabetic subjects. The GISIR database. Nutr Metab Cardiovasc Dis. 2008;18:624–31.PubMedCrossRefGoogle Scholar
  3. 3.
    Barker DJ, Eriksson JG, Forsén T, et al. Fetal origins of adult disease: strength of effects and biological basis. Int J Epidemiol. 2002;31:1235–9.PubMedCrossRefGoogle Scholar
  4. 4.
    Gluckman PD, Hanson MA, Cooper C, et al. Effect of in utero and early-life conditions on adult health and disease. N Engl J Med. 2008;359:61–73.PubMedCentralPubMedCrossRefGoogle Scholar
  5. 5.
    Stamler J, Vaccaro O, Neaton JD, et al. Diabetes, other risk factors, and 12-yr cardiovascular mortality for men screened in the Multiple Risk Factor Intervention Trial. Diabetes Care. 1993;16:434–44.PubMedCrossRefGoogle Scholar
  6. 6.••
    Mancia G, Fagard R, Narkiewicz K, et al. 2013 ESH/ESC Guidelines for the management of arterial hypertension: The Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens. 2013;31:1281–357. This is the updated version of European guidelines on arterial hypertension, including one section on treatment of patients with type 2 diabetes. It summarizes the evidence and advocates a blood pressure goal <140/85 mmHg. PubMedCrossRefGoogle Scholar
  7. 7.••
    Authors/Task Force Members, Rydén L, Grant PJ, Anker SD, et al. ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD: The Task Force on diabetes, pre-diabetes, and cardiovascular diseases of the European Society of Cardiology (ESC) and developed in collaboration with the European Association for the Study of Diabetes (EASD). Eur Heart J. 2013;34:3035–87. This document gives a full description of cardiovascular risk factors and their control in patients with type diabetes or impaired glucose metabolism. Also here the evidence base has led to the recommendation of a blood pressure goal < 140/85 mmHg. Google Scholar
  8. 8.•
    American Diabetes Association. Standards of medical care in diabetes--2013. Diabetes Care. 2013;36 Suppl 1:S11–66. The American view has changed somewhat during recent years and is now much more similar to the European view, but also stating different goals for younger and newly detected patients with diabetes. CrossRefGoogle Scholar
  9. 9.
    National Clinical Guideline Centre (UK). Hypertension: The clinical management of primary hypertension in Adults: Update of clinical guidelines 18 and 34 [Internet]. London: Royal College of Physicians (UK); 2011. Aug. Available from http://www.ncbi.nlm.nih.gov/books/NBK83274/.Google Scholar
  10. 10.
    Cederholm J, Gudbjörnsdottir S, Eliasson B, NDR, et al. Systolic blood pressure and risk of cardiovascular diseases in type 2 diabetes: an observational study from the Swedish national diabetes register. J Hypertens. 2010;28(10):2026–35.PubMedCrossRefGoogle Scholar
  11. 11.•
    Cederholm J, Gudbjörnsdottir S, Eliasson B, NDR, et al. Blood pressure and risk of cardiovascular diseases in type 2 diabetes: further findings from the Swedish National Diabetes Register (NDR-BPII). J Hypertens. 2012;30:2020–30. In this Swedish cohort study observational data have been analysed to state that there is no extra benefit in reducing blood pressure below 130 mmHg SBP. An increased mortality was noticed in subjects with attained very low SBP <110 mmHg. PubMedCrossRefGoogle Scholar
  12. 12.
    Cooper-DeHoff RM, Gong Y, Handberg EM, et al. Tight blood pressure control and cardiovascular outcomes among hypertensive patients with diabetes and coronary artery disease. JAMA. 2010;304:61–8.PubMedCentralPubMedCrossRefGoogle Scholar
  13. 13.•
    Redon J, Mancia G, Sleight P, ONTARGET Investigators, et al. Safety and efficacy of low blood pressures among patients with diabetes: subgroup analyses from the ONTARGET (ONgoing Telmisartan Alone and in combination with Ramipril Global Endpoint Trial). J Am Coll Cardiol. 2012;59:74–83. Data from this large-scale study has been used to show association between a low achieved SBP and increased risk of cardiovascular mortality in patients with treated hypertension and type 2 diabetes. PubMedCrossRefGoogle Scholar
  14. 14.
    Bangalore S, Kumar S, Lobach I, et al. Blood pressure targets in subjects with type 2 diabetes mellitus/impaired fasting glucose: observations from traditional and bayesian random-effects meta-analyses of randomized trials. Circulation. 2011;123:2799–810.PubMedCrossRefGoogle Scholar
  15. 15.
    ACCORD Study Group, Cushman WC, Evans GW, Byington RP, Goff Jr DC, Grimm Jr RH. Effects of intensive blood-pressure control in type 2 diabetes mellitus. N Engl J Med. 2010;362:1575–85.PubMedCrossRefGoogle Scholar
  16. 16.
    Turnbull F, Neal B, Algert C, Blood Pressure Lowering Treatment Trialists' Collaboration, et al. Effects of different blood pressure-lowering regimens on major cardiovascular events in individuals with and without diabetes mellitus: results of prospectively designed overviews of randomized trials. Arch Intern Med. 2005;165:1410–9.PubMedCrossRefGoogle Scholar
  17. 17.
    Heart Outcomes Prevention Evaluation (HOPE) Study Investigators. Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Lancet. 2000;355:253–9.CrossRefGoogle Scholar
  18. 18.
    Kostis JB, Wilson AC, Freudenberger RS, SHEP Collaborative Research Group, et al. Long-term effect of diuretic-based therapy on fatal outcomes in subjects with isolated systolic hypertension with and without diabetes. Am J Cardiol. 2005;95:29–35.PubMedCrossRefGoogle Scholar
  19. 19.
    Gaede P, Lund-Andersen H, Parving HH, et al. Effect of a multifactorial intervention on mortality in type 2 diabetes. N Engl J Med. 2008;358:580–91.PubMedCrossRefGoogle Scholar
  20. 20.
    Nilsson PM, Boutouyrie P, Cunha P, et al. Early vascular ageing in translation: from laboratory investigations to clinical applications in cardiovascular prevention. J Hypertens. 2013;31:1517–26.PubMedCrossRefGoogle Scholar
  21. 21.
    Nilsson PM, Tufvesson H, Leosdottir M, et al. Telomeres and cardiovascular disease risk: an update 2013. Transl Res. 2013;162(6):371–80.Google Scholar

Copyright information

© Springer Science+Business Media New York 2014

Authors and Affiliations

  1. 1.Department of Clinical Sciences, Skåne University HospitalLund UniversityMalmöSweden

Personalised recommendations